CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells |
| |
Authors: | Latinovic Olga Reitz Marvin Le Nhut M Foulke James S Fätkenheuer Gerd Lehmann Clara Redfield Robert R Heredia Alonso |
| |
Institution: | a Institute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD, USAb First Department of Internal Medicine, University of Cologne, Cologne, Germany |
| |
Abstract: | R5 HIV-1 strains resistant to the CCR5 antagonist Maraviroc (MVC) can use drug-bound CCR5. We demonstrate that MVC-resistant HIV-1 exhibits delayed kinetics of coreceptor engagement and fusion during drug-bound versus free CCR5 infection of cell lines. Antibodies directed against the second extracellular loop (ECL2) of CCR5 had greater antiviral activity against MVC-bound compared to MVC-free CCR5 infection. However, in PBMCs, only ECL2 CCR5 antibodies HGS004 and HGS101, but not 2D7, inhibited infection by MVC resistant HIV-1 more potently with MVC-bound than with free CCR5. In addition, HGS004 and HGS101, but not 2D7, restored the antiviral activity of MVC against resistant virus in PBMCs. In flow cytometric studies, CCR5 binding by the HGS mAbs, but not by 2D7, was increased when PBMCs were treated with MVC, suggesting MVC increases exposure of the relevant epitope. Thus, HGS004 and HGS101 have antiviral mechanisms distinct from 2D7 and could help overcome MVC resistance. |
| |
Keywords: | HIV-1 CCR5 CCR5 antagonists Maraviroc CCR5 antibodies Antagonist resistance |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|